Stocks › PVCT
PROVECTUS BIOPHARMACEUTICALS, INC.
PVCT·OTC·
United States·USD
United States·USD$0.05
-0.00 (-0.09%)
Close · Oct 7, 2026 · Close Prices from Tiingo.com
PVCT
PROVECTUS BIOPHARMACEUTICALS, INC. · OTC
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
PVCTS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of PVCT by members of U.S. Congress · 1 on record
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
 John J. DuncanHouse · R · TN |
PVCTPROVECTUS BIOPHARMACEUTICALS, INC. · Stock |
Purchase $1,001 - $15,000 |
Jun 12, 2014 | May 14, 2014 | Filing ↗ |
Whale Activity
Position changes in PVCT reported for 2016-09-30 by 3 tracked institutional filers
- Increased1
- New0
- Held1
- Decreased1
- Closed0
- No prior filing0
| Filer | Shares | Value | Change |
|---|---|---|---|
| Vanguard Group | 3.7M | $366K | decreased |
| Renaissance Technologies | 803.2K | $80K | increased |
| Millennium Management LLC | 500.0K | $26K | held |
KeyVex tracks a curated set of large 13F filers plus the largest positions in recent filings, so this is a sample of institutional activity, not the whole market.
Insider Trading
Net shares bought (+) or sold (−) on the open market by PVCT insiders, by quarter · Form 4
No open-market insider buys or sells in the last two years.
Recent Insider Transactions
166 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Morris Jeffrey Allen10% owner | Conversion | +264.3K | $2.86 | $756K | Aug 12, 2024 | Form 4 ↗ |
| Morris Jeffrey Allen10% owner | Conversion | +188.8K | $2.86 | $540K | May 8, 2023 | Form 4 ↗ |
| Raines HeatherCFO | Grant / award | +50.0K | $0.00 | $0 | Nov 10, 2020 | Form 4 ↗ |
| Lacy John IIIDirector | Grant / award | +100.0K | $0.00 | $0 | Nov 10, 2020 | Form 4 ↗ |
| Horowitz BruceChief Operating Officer · Director | Grant / award | +800.0K | $0.00 | $0 | Nov 10, 2020 | Form 4 ↗ |
| Raines HeatherChief Financial Officer | Grant / award | +50.0K | $0.00 | $0 | Mar 25, 2019 | Form 4 ↗ |
| Glass John RSee Remarks | Purchase | +115.9K | $0.05 | $6K | Dec 14, 2017 | Form 4 ↗ |
| Glass John RSee Remarks | Purchase | +84.1K | $0.05 | $4K | Dec 14, 2017 | Form 4 ↗ |
| CULPEPPER PETER RInterim CEO, CFO, COO | O | +106.0K | $1.00 | $106K | Mar 29, 2016 | Form 4 ↗ |
| CULPEPPER PETER RInterim CEO, CFO, COO | O | +27.3K | $1.00 | $27K | Mar 29, 2016 | Form 4 ↗ |
| CULPEPPER PETER RInterim CEO, CFO, COO | O | +133.3K | $1.00 | $133K | Mar 29, 2016 | Form 4 ↗ |
| WACHTER ERIC PHDChief Technology Officer · Director | O | +106.0K | $1.00 | $106K | Mar 29, 2016 | Form 4 ↗ |
| WACHTER ERIC PHDChief Technology Officer · Director | O | +200.9K | $1.00 | $201K | Mar 29, 2016 | Form 4 ↗ |
| Koe JanDirector | O | +100.0K | $1.25 | $125K | Mar 29, 2016 | Form 4 ↗ |
| Koe JanDirector | O | +100.0K | $1.25 | $125K | Mar 29, 2016 | Form 4 ↗ |
| WACHTER ERIC PHDChief Technology Officer | Option exercise | +120.0K | $1.02 | $122K | Dec 21, 2015 | Form 4 ↗ |
| CULPEPPER PETER RCFO & COO | Option exercise | +6,383 | $0.94 | $6K | Dec 9, 2015 | Form 4 ↗ |
| CULPEPPER PETER RCFO & COO | Option exercise | +138.8K | $0.94 | $131K | Dec 9, 2015 | Form 4 ↗ |
| WACHTER ERIC PHDChief Technology Officer | Option exercise | +185.0K | $1.02 | $189K | Jan 24, 2015 | Form 4 ↗ |
| CULPEPPER PETER RCFO & COO | Option exercise | +29.8K | $0.94 | $28K | Jan 7, 2015 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding PVCT · SEC Form N-PORT
Funds report their holdings by CUSIP, and PVCT could not be matched to one, so no fund holdings are shown.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
- Pershing EdwardSCHEDULE 13D/A · activist (13D) · 52.4M shares11.6%
Jul 22, 2026 · ↗
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming PROVECTUS BIOPHARMACEUTICALS, INC. as client
No lobbying filings found naming PROVECTUS BIOPHARMACEUTICALS, INC. as the client.
Government Contracts
Federal awards to PROVECTUS BIOPHARMACEUTICALS, INC. · USAspending
No federal contract awards found for PROVECTUS BIOPHARMACEUTICALS, INC..
U.S. Patents
Recent USPTO applications naming PROVECTUS BIOPHARMACEUTICALS, INC.
No USPTO patent applications found for PROVECTUS BIOPHARMACEUTICALS, INC..
Annual Financials
From PVCT's 10-K filings · XBRL
No annual XBRL figures on record for PVCT. KeyVex's fundamentals cover about 130 large companies so far.
Stock Splits
Every split and reverse split in the price history
- 1-for-300Reverse splitApr 11, 2002
Split dates and ratios from the price history · Close Prices from Tiingo.com
About PROVECTUS BIOPHARMACEUTICALS, INC.
From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersKNOXVILLE, TN
IncorporatedDE
SEC CIK0000315545 ↗
Former namesPROVECTUS PHARMACEUTICALS INC, PROVECTUS PHARMACEUTICAL INC, ZAMAGE DIGITAL IMAGING INC